date:May 23, 2012
by the FDA for treating skin disorders that are available to consumers.
The FDA is committed to taking enforcement action against companies that circumvent the drug approval process, said Janet Woodcock, M.D., director of FDA's Center for Drug Evaluation and Research. Consumers need to be confident that the drugs and medical products they use have been reviewed by FDA and are safe and effective.
To date, the FDA has not received adverse event reports about HybriSil. Consumers and health care